Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 1.00 |
| ▸ | BRD2 | P25440 | 9/20 | 1.00 |
| ▸ | BRD3 | Q15059 | 9/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 9/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 9/20 | 1.00 |
| ▸ | CACNA1A | O00555 | 1/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CCL2 | P13500 | 1/20 | 1.00 |
| ▸ | KCNA5 | P22460 | 1/20 | 1.00 |
| ▸ | TACR1 | P25103 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | BRDT | Q58F21 | 1/20 | 1.00 |
| ▸ | CREBBP | Q92793 | 1/20 | 1.00 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1904423 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL1906755 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12098810 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL29366680 | 1.00 | BRD4 (1.00) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL30014518 | 0.99 | BRD4 (0.98) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL29881331 | 0.99 | BRD4 (0.98) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL23318387 | 0.93 | BRD4 (0.86) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL18250031 | 0.91 | BRD4 (0.84) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL19068586 | 0.91 | BRD4 (0.83) | BRD4BRD2BRD3CYP3A4CYP2C9 | |
| SCHEMBL12099072 | 0.90 | BRD4 (1.00) | BRD4BRD2BRD3CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1073 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630883-B2 | Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes | JAPANESE FOUNDATION FOR CANCER RESEARCH (JP) | 2026-05-19 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| EP-4658687-A1 | IMMUNE CHECKPOINT BLOCKADE THERAPY FOR TREATING STAPHYLOCOCCUS AUREUS INFECTIONS | University of Rochester (US) | 2025-12-10 | — | — | EP | claimed |
| EP-3664807-B1 | METHODS AND MATERIALS FOR IDENTIFYING AND TREATING BET INHIBITOR-RESISTANT CANCERS | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-19 | — | — | EP | claimed |
| WO-2025151706-A1 | EPIGENETIC REAGENTS AND UTILIZATION OF CAR NK CELLS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-07-17 | — | — | WO | claimed |
| US-20250213689-A1 | IMMUNOGENIC COMPOSITION FOR THE TREATMENT OF CANCER | APGEN THERAPUETICS AB (SE) | 2025-07-03 | — | — | US | claimed |
| CN-115551917-B | Sequential targeting of cross-linked nanotherapeutics for the treatment of brain tumors | 加利福尼亚大学董事会 | 2025-06-13 | — | — | CN | claimed |
| US-20250177529-A1 | ACOUSTIC ENRICHMENT OF ADOPTIVE CELL TRANSFERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2025-06-05 | — | — | US | claimed |
| CN-120053487-A | Platelet rich suspension and gel prepared by in vitro differentiation of human pluripotent induced stem cells (iPSC) and preparation method thereof | 河络新图生物科技(上海)有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-12296009-B2 | Immunogenic composition for the treatment of cancer | APGEN THERAPUETICS AB (SE) | 2025-05-13 | — | — | US | claimed |
| US-11344546-B2 | Benzamide compounds | Recurium IP Holding, LLC (US) | 2022-05-31 | — | — | US | claimed |
| WO-2022081827-A1 | CHIMERIC CONJUGATES FOR DEGRADATION OF VIRAL AND HOST PROTEINS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| CN-114344467-A | Application of BET protein inhibitor in preparation of chronic graft-versus-host disease drug | 苏州大学 | 2022-04-15 | — | — | CN | claimed |
| US-11298354-B2 | Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-12 | — | — | US | claimed |
| CN-114317401-A | Method for promoting long-term stable passage of islet precursor cells | 浙江大学 | 2022-04-12 | — | — | CN | claimed |
| EP-3973967-A1 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | Astellas Institute for Regenerative Medicine (US) | 2022-03-30 | — | — | EP | claimed |
| EP-3969050-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | SAINT LOUIS UNIVERSITY (US) | 2022-03-17 | — | — | US | claimed |
| WO-2022046682-A1 | BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS | MDI BIOLOGICAL LABORATORY (US) | 2022-03-03 | — | — | WO | claimed |
| US-20220047596-A1 | COMBINATION OF PARP INHIBITOR AND BRD4 INHIBITOR FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079951-A1 | BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD | BRDT, PHKB, BET1 | BRD4 4/4885BRD2 8/4885BRD3 5/4885 |
| US-12630883-B2 | Test method of dividing blastic plasmacytoid dendritic cell neoplasm (BPDCN) into subtypes | BCL3, BRD4, BCL6 | BRD4 2/4885BRD2 23/4885BRD3 5/4885 |
| US-11344546-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | BRD4 24/4885BRD2 33/4885BRD3 36/4885 |
| US-11298354-B2 | Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors | HDAC9, HDAC7, HDAC8 | BRD4 15/4885BRD2 30/4885BRD3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.